Phaseline

Targets › POLLEN

POLLEN: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout Dec 2029.

Open in Phaseline: the race on POLLEN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Gilead SciencesBIC/LEN FDC
Combination of integrase strand transfer inhibitor and capsid inhibitor
INSR, POLLENPhase 2HIV-1-infectionDec 2029

Conditions

HIV-1-infection (1)

Modalities

small molecule (1)

Companies

Gilead Sciences (1)

Related targets

INSR (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.